Biomarker testing, treatment patterns and outcomes in previously treated pMMR or non-MSI-H metastatic colorectal cancer patients
Only 70.9% of mCRC patients received guideline-recommended MSI/MMR testing, indicating a need for improved testing rates. Additionally, only 27.1% of previously treated mCRC patients received SoC options (regorafenib/TAS-102). The real-world variability in treatment choices and a high rate of chemotherapy rechallenge in subsequent lines highlight an unmet need in this patient population.
Authors
- Mayur M. Amonkar (ORCID: https://orcid.org/0000-0003-4135-4211)
- David Cosgrove (ORCID: https://orcid.org/0000-0003-2700-5656)
- Ali Sartaj (ORCID: https://orcid.org/0000-0002-0878-3455)
- Kasey Estenson
- Rishi Jain (ORCID: https://orcid.org/0000-0003-2716-1499)
- Kaushal Desai (ORCID: https://orcid.org/0000-0002-8941-2858)
- Gregory Patton
- Sneha Sura
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Compass Oncology (US)
- Diagnostics for the Real World (United States) (US)
- Eisai (Japan) (JP)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1080/14796694.2025.2504246
- Citations
- 2
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.09